# SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

> **NCT00331864** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 531 (actual)

## Conditions studied

- Age Related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00331864
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2011-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331864, "SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00331864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*